Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy.
Jeffrey B WestMina N DinhJoel S BrownJingsong ZhangAlexander A R A AndersonRobert A GatenbyPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
Mathematical models can integrate evolutionary dynamics into multidrug cancer clinical trials. This has the potential to improve outcomes and to develop clinical trials in which these mathematical models are also used to estimate the mechanism(s) of treatment failure and explore alternative strategies to improve outcomes in future trials.
Keyphrases
- clinical trial
- prostate cancer
- cancer therapy
- drug resistant
- squamous cell carcinoma
- small cell lung cancer
- papillary thyroid
- radical prostatectomy
- phase ii
- genome wide
- risk assessment
- gene expression
- open label
- metabolic syndrome
- young adults
- human health
- combination therapy
- multidrug resistant
- dna methylation
- study protocol
- glycemic control
- replacement therapy
- childhood cancer